KALV
KalVista Pharmaceuticals
Stock NASDAQ – Stock Market Prices, News & Analysis
KalVista Pharmaceuticals Inc develops drugs for the treatment of rare diseases related to disorders in the kallikrein-kinin activation system, including hereditary angioedema.
KalVista Pharmaceuticals
KALV
KalVista Pharmaceuticals Inc develops drugs for the treatment of rare diseases related to disorders in the kallikrein-kinin activation system, including hereditary angioedema.
Price history of KalVista Pharmaceuticals
Price history of KalVista Pharmaceuticals
Performance & Momentum
Strategic Analysis
KalVista Pharmaceuticals • 2026
KalVista Pharmaceuticals positions itself in the highly specialized segment of rare diseases, specifically targeting dysfunctions of the plasma kallikrein system, with a focus on hereditary angioedema. Its model relies on the development of innovative treatments in a low-competitive therapeutic niche, enhancing the valuation potential linked to the rarity and medical urgency of these conditions.
- Specialization in a rare and underserved therapeutic segment
- Portfolio focused on conditions with a strong unmet medical need
- Track record of sustained positive valuation in the medium term
- Notable volatility with negative long-term performance
- Dependence on clinical and regulatory successes for valuation
Current momentum is moderately favorable, supported by positive dynamics over one and three years, indicating a resurgence of investor interest. The absence of recent news suggests a period of consolidation ahead of potential upcoming clinical or regulatory catalysts.
Similar stocks to KalVista Pharmaceuticals
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
